Is this Hikma's cue for a break out?Will Hikma break out after a 5 year H&S pattern,
now that it's making progress in the Covid-19 vaccine business?
PHARMA
AB=CD Pattern Replacement to Catch the TrendAURO Pharma is on marathon but a sprint marathon exhausts the athlete and the same happens to the stocks. AB=CD pattern would make the point D- a point of in flexion and fall all the way to POC level marked, from where again a buying opportunity can be tapped by the incumbent buyers and from the initiative buyer looking for a discounted entry .
Torrent pharmaHello !! torrent pharma is quite at all-time highs it just gave a very big up move on a day before last market day so it's more prone to be rangebound or a bit of retracement, if it doesn't break upper resistance and sustains a rangebound session can be seen but if it breaks the final resistance then it will be on the all-time highs so the target is difficult to give. #my_view #learner
CiplaHello!! Cipla is a famous company for pharma in India but I don't like much of pharma stocks, still this stock looks bullish for a short term and maybe will retrace a bit or rangebound because it has given a big move on last market day..... I think 745 tgt can be seen till 6th august 2020. #my_view #learner
Pennystock Wedgie. (ZOM)I will be trying to add 1% to this position around 13 cents p/share for a test on the recent bottom.
If breaks, will drop to the bottom of the wedge as we try to create the wave 5 of retracement.
Will look to add 0.5% if it does touch bottom of wedge.
This will be a longterm play with anticipation to breakout of the wedge for a impulse.
TORNTPHARMA SWING AND BREAKOUT TRADING IDEATORNTPHARMA SWING AND BREAKOUT TRADING IDEA
FRIENDS IF YOU LIKE THEN PLEASE LIKE AND SHARE.
Santen Analysis SNPHYFormations drawn
Rising Wedge
Scythe
I expect a breakdown of this weird wedge that has formed between a major trendline and a line of strong bounce areas
A very good potential pharma company to invest for good returns.One can trade in this script with immediate target of 570 followed by 610 and higher before stock split, keep stop loss at 500. Good luck and have a great profitable day.
For long term investors keep it in your portfolio and hold for multi fold returns.
for more you can visit my site 5nancial.blogspot.com
BUY GUFIC BIO FOR INVESTMENTGUFIC BIO PERFECT ROUNDING BOTTOM PATTERN ON CHARTS, PERFECT PICK FOR MEDIUM TERM INVESTMENTS. CMP -78
BULLISH MOVES ON MONDAY [AUDNZD]The price failed to break our support zone so many times, it seems like that is an area where buyers are stepping in and push the price higher
any other ideas?? please comment your idea
8p/9.15p 1st targets - low downside / undervaluedPlacing was at 6.15p
Jupiter fund seller out - TR1 to confirm
BoD own 11% of the company
Acquisition of hVIVO back in December 2019
New presentation online
at £28.6m mcap we are undervalued
I have 8p as 1st target but we could breakout eventually & head to 9.15p then pullback to 8p & continue the bull trend after.
Will re-evaluate once we hit 8p.
Company looks very impressive so not afraid to add further on weakness.
Long biased w/ recent settlement with Apotex and tight range.21-May-20 16:10 ET
AMRN
Amarin announces trial to evaluate effects of VASCEPA on patients with COVID-19 (7.28 -0.18)
Amarin today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group.
The company states, "Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus."
14-May-20 14:52 ET
AMRN
Amarin announces VASCEPA data from prespecified and post hoc analyses of REDUCE-IT study (7.64 +0.22)
Amarin today announced that data from the REDUCE-IT study presented at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions,showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001).
The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors.
Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively.
In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).
$EVOK- Evoke Pharma IncWOW, looks pretty cool. Do I want it though, not right now, no...
Its starting to build up is how I look at it. From 3.75 to 4.15 is amazing buying power for you to actually make some AMAZING gains....
Invest Smart
Can't predict the future but it looks promising...
$MNK One last HoorahTwo reasons for posting this chart.
1) MNK is a long standing established generic and specialty manufacturer with products that have real usage. This is NOT a one hit wonder biotech. It would be bought out before full bankruptcy.
2) More importantly, when was the last time you've seen a CLEAR bullish divergence on a MONTHLY chart?
This will be a bag I hold probably until the end of 2020, but I expect it's first leg breaking out of its downtrend within the next 6 weeks.
A Monthly bullish divergence MUST not be ignored. If you have money you are not actively trading with, THIS is where you put it.
As you can see the accumulation volume over the last 6 months is there as well.
Weekly has bullish divergences as well.
On a shorter time frame, the daily is flagging. Breakout point 3.20 with target of 5 dollars.
ABBOTT INDIA - taking a pause nowNSE:ABBOTINDIA is facing a huge over head supply now.
Longs are doing profit booking.
5 Stocks we are looking into for the Covid-19 VaccineFirst off, please don't take anything I say seriously or as financial advice. As always, this is on an opinion based basis. That being said, let me get into my insights. There was rumors that AstraZeneca wanted to merge w/ Gilead. However, it looks like this may not happen. Until, the books are closed don't get your hopes up, but invest as if you expect something like this to go down. As far as stocks such as Pfizer, Pfizer so far is greatly underrated in terms of growth potential during the vaccine trials period, and likely because of that it is due for a bullish run quite soon. NVAX and Moderna, I believe already have the most stable growth potential given the logarithmic curves. These 5 stocks may be quite interesting to look at given all these giants from Pfizer to Moderna to Gilead are working on being the forefront of the expected Covid19 vaccine delivery. If this is a huge revenue booster, that means obvious profit turn over potential. Also, it is likely better for a buy entry previous to August, September, and the winter when hype may start increasing. Lots of the excitement have very recently slowed down, and you likely don't want to wait for the hype if you do long term holds.
Nifty Pharma - Bull Territory - BTFD - Above 9400 levelsNSE:CNXPHARMA has come into the bull territory, one may use the opportunity to buy on dips whenever it happens.
